首页> 外国专利> METHOD FOR TREATING ASTHMA (OPTIONS) AND METHOD FOR REDUCING THE RISK OF INFECTIONS DEVELOPMENT BY β-HYDROXY-β-METHYLBUTYRATE

METHOD FOR TREATING ASTHMA (OPTIONS) AND METHOD FOR REDUCING THE RISK OF INFECTIONS DEVELOPMENT BY β-HYDROXY-β-METHYLBUTYRATE

机译:治疗哮喘(选项)的方法和减少β-羟基-β-甲基丁酸酯感染的风险的方法

摘要

1. A method of treating asthma in an individual characterized by an imbalance in the content of cytokines of the first and second types, which comprises administering to the individual β-hydroxy-β-methylbutyrate in an amount effective to modulate the imbalance in the production of cytokines of the first and second types. The method according to claim 1, wherein the ratio of the content of cytokines of the first type to the content of cytokines of the second type increases as a result of administration of β-hydroxy-β-methylbutyrate. The method according to claim 2, in which the content of the first type of cytokines increases without increasing the content of the second type of cytokines. The method according to claim 2, wherein the effective amount of β-hydroxy-β-methylbutyrate is in the range of from about 0.5 to about 10 g per day. The method according to claim 2, wherein β-hydroxy-β-methylbutyrate is introduced as part of a nutritional product that further comprises at least one fat and / or protein and / or carbohydrate. The method of claim 2, wherein type 1 cytokines are selected from the group comprising interferon y, interleukin 2 and interleukin 12, and type 2 cytokines are selected from the group comprising interleukin 4, interleukin 5, interleukin 13, and interleukin 10.7. The method of claim 1, wherein the amount of β-hydroxy-β-methylbutyrate is effective in preventing a decrease in FEV. The method according to claim 1, wherein the amount of β-hydroxy-β-methylbutyrate is effective to maintain a baseline FEV of greater than 80%. The method of claim 1, wherein the type 1 cytokines are interferons or interleukin 2, and the type 2 cytokines are interleukin 4.10. A method for treating asthma in an individual at risk for developing asthma, comprising administering to said individual
机译:1.一种治疗个体的哮喘的方法,其特征在于第一和第二类型的细胞因子含量不平衡,该方法包括以有效调节量调节生产中的不平衡的量向个体施用β-羟基-β-甲基丁酸酯。第一和第二类型的细胞因子。 2.根据权利要求1所述的方法,其中,由于施用β-羟基-β-甲基丁酸酯,第一类型的细胞因子的含量与第二类型的细胞因子的含量的比率增加。 3.根据权利要求2的方法,其中在不增加第二种细胞因子的含量的情况下增加第一类细胞因子的含量。 3.根据权利要求2的方法,其中所述β-羟基-β-甲基丁酸酯的有效量为每天约0.5至约10g。 3.根据权利要求2所述的方法,其中将β-羟基-β-甲基丁酸酯作为营养产品的一部分引入,所述营养产品还包含至少一种脂肪和/或蛋白质和/或碳水化合物。 3.权利要求2的方法,其中1型细胞因子选自干扰素γ,白介素2和白介素12,并且2型细胞因子选自白介素4,白介素5,白介素13和白介素10.7。 3.根据权利要求1所述的方法,其中,所述β-羟基-β-甲基丁酸酯的量可有效防止FEV的降低。 2.根据权利要求1所述的方法,其中所述β-羟基-β-甲基丁酸酯的量有效地维持基线FEV大于80%。 2.权利要求1的方法,其中1型细胞因子是干扰素或白介素2,2型细胞因子是白介素4.10。一种在有发展成哮喘风险的个体中治疗哮喘的方法,包括对所述个体给药

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号